查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771646

美國氣霧劑給藥裝置市場規模、佔有率、趨勢分析報告（按類型、應用、分銷管道、細分市場預測，2025-2030 年）

U.S. Aerosol Drug Delivery Devices Market Size, Share & Trends Analysis Report By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國氣霧劑給藥裝置市場規模將達到 112.7 億美元，2025 年至 2030 年的複合年成長率將達到 15.1%。

其背景是呼吸系統疾病的盛行率不斷上升、吸入器技術的進步、醫療保健意識的不斷增強以及家庭治療需求的不斷成長。根據美國肺臟協會的估計，到2022年，約有1,170萬人（占美國成年人的4.6%）將被診斷出患有慢性阻塞性肺病（COPD），其中包括慢性支氣管炎和肺氣腫。

此外，世界衛生組織預測，到2030年，慢性阻塞性肺病、肺癌和結核病等危及生命的呼吸道疾病將佔全球死亡人數的近五分之一。這些因素促使吸入器和霧化器等氣霧劑裝置的廣泛使用。人們對家庭醫療保健的日益重視也促進了氣霧劑給藥裝置的普及。

患者和醫療保健提供者都希望在家中舒適地接受治療，從而減少去醫院就診的需要和相關的醫療費用。這種轉變推動了對攜帶式、方便用戶使用的氣霧劑給藥裝置的需求，這些裝置有助於呼吸系統疾病的自我管理。電子商務平台和線上藥局的普及進一步提高了此類設備的可近性。

氣霧劑給藥裝置的技術進步將顯著推動市場成長。配備感測器的智慧吸入器可監測藥物使用情況並提高服藥依從性，正日益普及。技術創新包括雙腔直吸式吸入器 (DPI)、呼吸驅動定量吸入器 (MDI) 和環保推進劑。這些技術提高了藥物傳輸效率並方便了患者使用。例如，Aerogen 的振動篩孔式噴霧器技術現已在美國醫院廣泛採用，它就是一項創新，旨在改善機械通氣和非機械通氣患者的治療。這些進步使這些設備使用起來更簡單、更實用，從而促進了患者和醫療保健提供者的採用。

新冠疫情對美國市場產生了正面影響。新冠疫情及其相關呼吸系統疾病的增多，尤其影響到需要持續呼吸照護的氣喘和慢性阻塞性肺病患者，導致吸入器和霧化器的需求激增。家庭醫療保健和遠端醫療的轉變推動了攜帶式和智慧吸入設備的普及。然而，疫情擾亂了供應鏈，導致原料短缺和生產延誤，暫時抑制了市場成長。此外，由於醫院優先考慮重症監護，非緊急呼吸護理和手術數量有所下降。儘管存在這些挫折，但這場危機加速了數位醫療領域的創新，為美國市場的長期前景提供了支撐。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場趨勢與展望
  • 目前可用的氣霧劑藥物的配方和成本分析。
  • 定價分析
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國氣霧劑給藥裝置市場分析工具：PESTEL
    • 政治與法律
    • 經濟與社會
    • 科技
  • 美國氣霧劑給藥裝置市場分析工具：波特五力分析

第4章美國氣霧劑給藥裝置市場：類型估計與趨勢分析

  • 美國氣霧劑給藥裝置市場：類型變化分析
  • 美國氣霧劑給藥裝置市場：細分儀表板
  • 2024 年和 2030 年類型趨勢和市場佔有率分析
  • 按類型
  • 吸入器
    • 加壓定量吸入器（pMDI）
    • 乾粉吸入器（DPI）
  • 噴霧器
    • 噴射
    • 網
    • 超音波

第5章美國氣霧劑給藥裝置市場：應用評估與趨勢分析

  • 美國氣霧劑給藥裝置市場：應用趨勢分析
  • 美國氣霧劑給藥裝置市場：應用細分儀表板
  • 2024 年和 2030 年應用趨勢和市場佔有率分析
  • 按用途
  • COPD
  • 氣喘
  • 囊腫纖維化
  • 其他（肺動脈高壓（PAH）等）

第6章美國氣霧劑給藥裝置市場：通路評估與趨勢分析

  • 美國氣霧劑給藥裝置市場：通路差異分析
  • 美國氣霧劑給藥裝置市場：分銷通路細分儀表板
  • 2024 年和 2030 年分銷通路趨勢和市場佔有率分析
  • 按分銷管道
  • 零售藥局
  • 網路藥局
  • 設施藥房

第7章 競爭態勢

  • 公司分類
  • 2024年企業市場地位/佔有率分析
  • Company Share Analysis
  • 公司簡介/上市公司
    • AptarGroup, Inc.
    • Koninklijke Philips NV
    • AstraZeneca
    • Novartis AG
    • Sanofi
    • OMRON Corporation
    • Medline Industries, LP.
    • GF Health Products, Inc.
    • DRIVE MEDICAL GMBH &CO. KG
    • Teva Pharmaceutical Industries Ltd.
    • Aerogen（Stamford Devices Limited Group）
    • Sensirion AG
    • PARI Respiratory Equipment, Inc.
    • Catalent, Inc.
    • Pfizer Inc.
    • Beurer GmbH
Product Code: GVR-4-68040-615-4

Market Size & Trends:

The U.S. aerosol drug delivery devices market size was estimated at USD 11.27 billion in 2024 and is expected to grow at a CAGR of 15.1% from 2025 to 2030. This is attributed to the rising prevalence of respiratory diseases, advancements in inhaler technology, increasing healthcare awareness, and the growing demand for home-based treatments. According to estimates from the American Lung Association, in 2022, approximately 11.7 million people, or 4.6% of adults, were diagnosed with COPD, including chronic bronchitis and emphysema.

In addition, the WHO projects that by 2030, life-threatening respiratory diseases such as COPD, lung cancer, and tuberculosis will be responsible for nearly one in five deaths worldwide. Such factors contribute to the widespread adoption of aerosol devices, including inhalers and nebulizers. The growing emphasis on home healthcare contributes to the increased adoption of aerosol drug delivery devices.

Patients and healthcare providers are seeking treatments administered in the comfort of home, reducing the need for hospital visits and associated healthcare costs. This shift drives demand for portable, user-friendly aerosol delivery devices that facilitate self-management of respiratory conditions. The availability of e-commerce platforms and online pharmacies has further enhanced accessibility to these devices.

Technological advancements in aerosol drug delivery devices significantly propel market growth. Smart inhalers with sensors to monitor medication usage and improve adherence are becoming increasingly prevalent. Innovations include dual-chamber DPIs, breath-actuated MDIs, and environmentally friendly propellants. These technologies enhance drug delivery efficiency and patient convenience. For instance, Aerogen's vibrating mesh nebulizer technology, now widely adopted in U.S. hospitals, exemplifies innovation in improving treatment for ventilated and non-ventilated patients. Such advancements make devices more straightforward and practical, encouraging patient and healthcare provider adoption.

The COVID-19 pandemic had a positive impact on the U.S. market. The demand for inhalers and nebulizers surged as COVID-19 and related respiratory conditions increased, particularly affecting patients with asthma and COPD who required ongoing respiratory care. The shift toward at-home healthcare and telemedicine drove the adoption of portable and smart inhalation devices. However, the pandemic disrupted supply chains, leading to raw material shortages and production delays, temporarily constraining market growth. In addition, hospitals prioritized critical COVID-19 care, causing a decline in non-urgent respiratory treatments and procedures. Despite these setbacks, the crisis accelerated digital health innovation and supported the long-term outlook of the U.S. market.

U.S. Aerosol Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aerosol drug delivery devices market report based on type, application, and distribution channel:

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Inhaler
    • Pressurized Metered-Dose Inhaler (pMDI)
    • Dry-Powder Inhaler (DPI)
  • Nebulizer
    • Jet
    • Mesh
    • Active
    • Passive
    • Ultrasonic
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • COPD
  • Asthma
  • Cystic Fibrosis
  • Other (Pulmonary Arterial Hypertension (PAH), etc.)
  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Retail Pharmacies
  • Online Pharmacies
  • Institutional Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Aerosol Drug Delivery Devices Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Type segment outlook
      • 2.1.2.2. Application segment outlook
      • 2.1.2.3. Distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Currently Available Aerosol Drug Formulations and Cost Analysis
  • 3.4. Pricing Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Rising prevalence of respiratory diseases
      • 3.5.1.2. Technological advancements
      • 3.5.1.3. Rising geriatric population
      • 3.5.1.4. Increasing awareness of self-medication and home healthcare
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. High cost of devices
    • 3.5.3. Market Opportunity Analysis
    • 3.5.4. Market Challenges Analysis
  • 3.6. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: PESTEL
    • 3.6.1. Political & Legal
    • 3.6.2. Economic & Social
    • 3.6.3. Technology
  • 3.7. U.S. Aerosol Drug Delivery Devices Market Analysis Tools: Porter's

Chapter 4. U.S. Aerosol Drug Delivery Devices Market: Type Estimates & Trend Analysis

  • 4.1. U.S. Aerosol Drug Delivery Devices Market: Type Movement Analysis
  • 4.2. U.S. Aerosol Drug Delivery Devices Market: Type Segment Dashboard
  • 4.3. Type Movement & Market Share Analysis, 2024 & 2030
  • 4.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Type
  • 4.5. Inhaler
    • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.2. Pressurized Metered-Dose Inhaler (pMDI)
      • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Dry-Powder Inhaler (DPI)
      • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6. Nebulizer
    • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.2. Jet
      • 4.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3. Mesh
      • 4.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
      • 4.6.3.2. Active
        • 4.6.3.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
      • 4.6.3.3. Passive
        • 4.6.3.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.4. Ultrasonic
      • 4.6.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aerosol Drug Delivery Devices Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Aerosol Drug Delivery Devices Market: Application Movement Analysis
  • 5.2. U.S. Aerosol Drug Delivery Devices Market: Application Segment Dashboard
  • 5.3. Application Movement & Market Share Analysis, 2024 & 2030
  • 5.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Application
  • 5.5. COPD
    • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.6. Asthma
    • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.7. Cystic Fibrosis
    • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.8. Other (Pulmonary Arterial Hypertension (PAH), etc.)
    • 5.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Movement Analysis
  • 6.2. U.S. Aerosol Drug Delivery Devices Market: Distribution Channel Segment Dashboard
  • 6.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2030
  • 6.4. U.S. Aerosol Drug Delivery Devices Market Estimates & Forecast, by Distribution Channel
  • 6.5. Retail Pharmacies
    • 6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.7. Institutional Pharmacies
    • 6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position/Share Analysis, 2024
  • 7.3. Company Share Analysis
  • 7.4. Company Profiles/Listing
    • 7.4.1. AptarGroup, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments
    • 7.4.2. Koninklijke Philips N.V.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments
    • 7.4.3. AstraZeneca
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments
    • 7.4.4. Novartis AG
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments
    • 7.4.5. Sanofi
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments
    • 7.4.6. OMRON Corporation
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments
    • 7.4.7. Medline Industries, LP.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments
    • 7.4.8. GF Health Products, Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments
    • 7.4.9. DRIVE MEDICAL GMBH & CO. KG
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments
    • 7.4.10. Teva Pharmaceutical Industries Ltd.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments
    • 7.4.11. Aerogen (Stamford Devices Limited Group)
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments
    • 7.4.12. Sensirion AG
      • 7.4.12.1. Participant's Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Recent Developments
    • 7.4.13. PARI Respiratory Equipment, Inc.
      • 7.4.13.1. Participant's Overview
      • 7.4.13.2. Financial Performance
      • 7.4.13.3. Product Benchmarking
      • 7.4.13.4. Recent Developments
    • 7.4.14. Catalent, Inc.
      • 7.4.14.1. Participant's Overview
      • 7.4.14.2. Financial Performance
      • 7.4.14.3. Product Benchmarking
      • 7.4.14.4. Recent Developments
    • 7.4.15. Pfizer Inc.
      • 7.4.15.1. Participant's Overview
      • 7.4.15.2. Financial Performance
      • 7.4.15.3. Product Benchmarking
      • 7.4.15.4. Recent Developments
    • 7.4.16. Beurer GmbH
      • 7.4.16.1. Participant's Overview
      • 7.4.16.2. Financial Performance
      • 7.4.16.3. Product Benchmarking
      • 7.4.16.4. Recent Developments

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. aerosol drug delivery devices market revenue estimates and forecast, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. aerosol drug delivery devices market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. aerosol drug delivery devices market revenue estimates and forecast, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 US Aerosol Drug Delivery Devices Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for Market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Type segment outlook
  • Fig. 11 Application segment outlook
  • Fig. 12 Distribution Channel segment outlook
  • Fig. 13 Competitive landscape
  • Fig. 14 US Aerosol Drug Delivery Devices Market: Market dynamics
  • Fig. 15 US Aerosol Drug Delivery Devices Market: Porter's analysis
  • Fig. 16 US Aerosol Drug Delivery Devices Market: PESTLE analysis
  • Fig. 17 US Aerosol Drug Delivery Devices Market: Type segment dashboard
  • Fig. 18 US Aerosol Drug Delivery Devices Market: Type movement share analysis
  • Fig. 19 Inhaler Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Pressurized Metered-Dose Inhaler (PDMI) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Dry-Powder Inhaler (DPI) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Nebulizers Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Jet Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Mesh Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Active Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Passive Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Ultrasonic Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 US Aerosol Drug Delivery Devices Market: Application segment dashboard
  • Fig. 29 US Aerosol Drug Delivery Devices Market: Application Movement Share Analysis
  • Fig. 30 Asthma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Chronic Obstructive Pulmonary Disease (COPD) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Cystic Fibrosis Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Other (Pulmonary Arterial Hypertension (PAH), etc) Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 US Aerosol Drug Delivery Devices Market: Distribution Channel Segment Dashboard
  • Fig. 35 US Aerosol Drug Delivery Devices Market: Distribution Channel Movement Share Analysis
  • Fig. 36 Retail Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Institutional Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Online Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Company categorization
  • Fig. 40 Company Market position analysis, 2024
  • Fig. 41 Strategic framework